stockrowRevvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) Return on equity
Revvity Inc.'s return on equity over the twelve months to 30 September 2026 was 0.00%, down 3.2 percentage points from fiscal 2025 (3.23%). Over the past ten years it has ranged from 3.23% (fiscal 2025) to 22.2% (fiscal 2020) — the current reading is the lowest in ten years. That is in line with the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 3.23% | (0.25) |
| FY2024 | 3.48% | (5.61) |
| FY2023 | 9.09% | 1.25 |
| FY2022 | 7.84% | (9.50) |
| FY2021 | 17.3% | (4.89) |
| FY2020 | 22.2% | 13.80 |
| FY2019 | 8.43% | (0.92) |
| FY2018 | 9.35% | (3.22) |
| FY2017 | 12.6% | 1.58 |
| FY2016 | 11.0% | 0.76 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 153.9% |
| MEDP Medpace Holdings, Inc. compare | 117.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| QGEN QIAGEN N.V. compare | 11.9% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| ICLR ICON PLC compare | 4.86% |
| CRL Charles River Laboratories International, Inc. compare | 1.21% |
| RVTY Revvity Inc. | 0.00% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement